Analisi dell’efficacia dei trattamenti precoci per COVID-19. I trattamenti non sostituiscono i vaccini e altre misure. Tutti i mezzi pratici, efficaci e sicuri dovrebbero essere utilizzati. L’eliminazione del COVID-19 è una corsa contro l’evoluzione virale. Nessun trattamento, vaccino o intervento è disponibile al 100% ed efficace per tutte le varianti attuali e future. Negare l’efficacia di qualsiasi metodo aumenta il rischio che il COVID-19 diventi endemico e aumenta la mortalità, la morbilità e i danni collaterali.

Early treatments approved by >2 countries. 60 countries have officially approved treatments. Details.

Studi recenti (vedere le pagine dei singoli trattamenti per tutti gli studi):

  • Aug 31MetaBen-Eltriki et al., Journal of the American College of Nutrition, doi:10.1080/07315724.2021.1951891 (Peer Reviewed) (meta analysis)meta-analysisAssociation between Vitamin D Status and Risk of Developing Severe COVID-19 Infection: A Meta-Analysis of Observational StudiesDetails   Meta analysis of 24 observational studies with 3,637 participants, showing low vitamin D status associated with a higher risk of death and a higher risk of developing severe COVID-19 pneumonia.
  • Aug 27LateShinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4 (Peer Reviewed)no recov., ↓37.1%, p=0.01Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical TrialDetails   RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
  • Aug 26LevelsGolabi et al., Zenodo, doi:10.5281/zenodo.5266352 (Preprint)The Association between Vitamin D and Zinc Status with the Disease Onset and Progression of Clinical Symptoms among Outpatients Infected with COVID-19 and Non-Infected Participants: A Cross-Sectional StudyDetails   Analysis of vitamin D and zinc levels in 53 PCR+ outpatients and 53 controls, showing lower zinc levels in COVID-19 patients, and increased risk of symptomatic cases with vitamin D deficiency. Currently only the abstract is available.
  • Aug 25MetaVarikasuvu (Preprint) (meta analysis)meta-analysisCOVID-19 and Vitamin D (Co-VIVID Study): a systematic review and meta-analysis of randomized controlled trialsDetails   Meta analysis of 6 vitamin D treatment RCTs, showing statistically significant improvements for pooled outcomes and PCR positivity, and positive but not statistically significant improvements for mortality, mechanical ventilation, ICU adm..
  • Aug 25EarlyRodrigues et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2021.106428 (Peer Reviewed)hosp., ↑200.0%, p=1.00Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearanceDetails   RCT 84 low risk patients, 42 treated with HCQ/AZ, showing no significant differences. There was only one hospitalization which was in the treatment arm.
  • Aug 25PrEPNaggie et al., medRxiv, doi:10.1101/2021.08.19.21262275 (Preprint)symp. case, ↓23.5%, p=0.18Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ)Details   RCT 1,360 healthcare workers in the USA showing OR 0.75 [0.49-1.15] for confirmed or suspected COVID-19 clinical infection by day 30. There were no significant safety issues. Authors note that pooling the results with the COVID PREP study..
  • Aug 24PrEPPatil et al., Research Square, doi:10.21203/rs.3.rs-805748/v1 (Preprint)death, ↓65.9%, p=0.10A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic DiseasesDetails   Prospective study of 9,212 autoimmune rheumatic disease patients showing lower mortality with HCQ, without reaching statistical significance. Authors incorrectly state “HCQ use did not influence occurrence of COVID-19 (RR = 0.909, CI..
  • Aug 24LateAlmoosa et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.022 (Peer Reviewed)death, ↑42.3%, p=0.10Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative StudyDetails   Retrospective 226 COVID-19 pneumonia patients, 110 treated with favipiravir, showing higher mortality (p=0.1) and ICU admission (p=0.02) with treatment in multivariate analysis.
  • Aug 23LateReis et al., Preprint (Preprint)death, ↓29.3%, p=0.26Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: The Together randomized platform clinical trialDetails   Together Trial preprint showing significantly lower hospitalization/extended ER visits with treatment, per-protocol analysis RR 0.34 [0.20-0.54]; ITT analysis RR 0.71 [0.54-0.93]. Adherence was only 73.2%. Symptom onset was unspecified or..
  • Aug 20In SilicoSong et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1964601 (Peer Reviewed)Vitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational studyDetailsIn Silico study suggesting that vitamin D3 and its biologically active hydroxyderivatives can serve as an TMPRSS2 inhibitor, and inhibit ACE2 binding with the SARS-CoV-2 RBD.
  • Aug 19In SilicoGonzález-Paz et al., Biophysical Chemistry, doi:10.1016/j.bpc.2021.106677 (Peer Reviewed)Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approachDetailsIn SIlico analysis of the components of ivermectin (avermectin-B1a and avermectin-B1b), suggesting different and complementary inhibitory activity of each component, with an affinity of avermectin-B1b for viral structures, and of avermect..
  • Aug 19LateDiaz et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab698 (Peer Reviewed)death, ↓34.7%, p=0.01Remdesivir and Mortality in Patients with COVID-19Details   Retrospective 1138 hospitalized patients in the USA, 286 treated with remdesivir, showing lower mortality with treatment.
  • Aug 18MetaNeil et al., Research Gate, doi:10.13140/RG.2.2.19703.75680 (Preprint) (meta analysis)meta-analysisBayesian hypothesis testing and hierarchical modelling of ivermectin effectiveness in treating Covid-19Details   Updated Bayesian analysis of a subset of ivermectin trials showing that there is strong evidence to support a causal link between ivermectin and COVID-19 severity and mortality, and that the result is robust in sensitivity analysis, inclu..
  • Aug 17In SilicoGonzález-Paz et al., Journal of Molecular Liquids, doi:10.1016/j.molliq.2021.117284 (Peer Reviewed)Structural Deformability Induced in Proteins of Potential Interest Associated with COVID-19 by binding of Homologues present in Ivermectin: Comparative Study Based in Elastic Networks ModelsDetailsIn Silico elastic network model analysis of ivermectin components (avermectin-B1a and avermectin-B1b) providing a biophysical and computational perspective of proposed multi-target activity of ivermectin for COVID-19.
  • Aug 17EarlyBaxter et al., medRxiv, doi:10.1101/2021.08.16.21262044 (Preprint)hosp., ↓65.3%, p=1.00Rapid initiation of nasal saline irrigation: hospitalizations in COVID-19 patients randomized to alkalinization or povidone-iodine compared to a national datasetDetails   Small RCT 79 PCR+ patients 55+ comparing pressure-based nasal irrigation with povidone-iodine and sodium bicarbonate, showing improved recovery with povidone-iodine, and 0/37 COVID-19 related hospitalizations for povidone-iodine compared ..
  • Aug 15EarlyKoshak et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769 (Peer Reviewed)hosp., ↓74.7%, p=0.37Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trialDetails   RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. NCT04401202. 500mg Nigella sativa oil (MARNYS Cuminmar) twice daily for 10 days.
  • Aug 13LateHosseini et al., medRxiv, doi:10.1101/2021.08.13.21261992 (Preprint)Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trialDetails   Single arm remdesivir trial with 145 hospitalized patients showing no statistically significant difference between “early” and “late” administration, however the treatment delays may be better described as late and ver..
  • Aug 12ReviewHoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01254-3 (Review) (Peer Reviewed)reviewRepurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanismsDetails   Review of the mechanisms of action and clinical studies for the treatment of COVID-19 with FIASMA antidepressants such as fluoxetine, fluvoxamine, paroxetine, escitalopram, or amitriptyline.
  • Aug 12Levelsdi Filippo et al, The Journal of Clinical Endocrinology & Metabolism, doi:10.1210/clinem/dgab599 (Peer Reviewed)death, ↓10.7%, p=1.00Vitamin D levels associate with blood glucose and BMI in COVID-19 patients predicting disease severityDetails   Retrospective 88 patients in Italy, showing vitamin D deficiency associated with severe cases, blood glucose, and BMI.
  • Aug 12LateElavarasi et al., medRxiv, doi:10.1101/2021.08.10.21261855 (Preprint)death, ↓19.6%, p=0.12Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India – a cohort studyDetails   Retrospective 2017 hospitalized patients in India, showing lower mortality with ivermectin treatment in unadjusted results. No group details are provided and this result is subject to confounding by indication.
  • Aug 12N/APedroso et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603 (Peer Reviewed)Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent responseDetails   Retrospective 45 healthcare workes in Brazil, showing lower creation of antibodies with multiple doses of ivermectin, which may be expected due to the antiviral activity as demonstrated in multiple studies. Authors appear unaware of these..
  • Aug 10LevelsAlpcan et al., Epidemiology & Infection, doi:10.1017/S0950268821001825 (Peer Reviewed)cases, ↓44.6%, p=0.0004Vitamin D levels in children with COVID-19: a report from TurkeyDetails   Retrospective 75 COVID-19 hospitalized pediatric patients in Turkey and 80 healthy controls, showing significantly lower vitamin D levels in COVID-19 patients.
  • Aug 10NewsLa Pampa, Argentina (News)death, ↓27.4%La Pampa expondrá a la comunidad científica los resultados del Programa de Intervención Monitoreado de IvermectinaDetails   News report on the use of ivermectin in La Pampa, Argentina, showing lower mortality with treatment.
  • Aug 10PEPShabani et al., Pulmonary Pharmacology & Therapeutics, doi:10.1016/j.pupt.2021.102069 (Peer Reviewed)symp. case, ↓19.0%, p=1.00Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in Close-Contact with Patients with Covid-19Details   Small PEP trial with 51 HCQ patients, not showing a significant difference in cases. IRCT20130917014693N10.
  • Aug 10NewsCalderón et al., News Report (News)newsMantiene Hospital Mónica Pretelini bajo índice de muertes Covid de mujeres embarazadasDetails   News report on the use of nitazoxanide for pregnant COVID-19 patients in a clinic in Mexico, reporting significant improvements in hospitalization and mortality compared to locations without treatment.
  • Aug 9LateKuno et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab256 (Peer Reviewed)death, ↓0.9%, p=0.96The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroidsDetails   PSM retrospective 3,372 hospitalized patients in the USA treated with steroids, showing no significant difference in mortality with remdesivir, but a lower risk of acute kidney injury.
  • Aug 6ReviewKow et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441 (Review) (Peer Reviewed)reviewPitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19Details   Review of sample size calculations in ivermectin RCTs, showing that existing RCTs are very underpowered.
  • Aug 6EarlyTogether Trial (News)death, ↓18.0%, p=0.54Early Treatment of COVID-19 with Repurposed Therapies: The TOGETHER Adaptive Platform TrialDetails   Preliminary report from the Together Trial showing mortality RR 0.82 [0.44-1.52]. The trial randomization chart suggests major problems and does not match the protocol. Trial week 43, the first week for 3 dose ivermectin, shows ~3x pati..
  • Aug 5LevelsNimavat et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2021.102661 (Peer Reviewed)death, ↓50.4%, p=0.17Vitamin D deficiency and COVID-19: A case-control study at a tertiary care hospital in IndiaDetails   Case control study with 156 PCR+ cases in India and 204 controls, showing more frequent vitamin D deficiency in COVID-19 patients, and an association between lower vitamin D levels and COVID-19 severity.
  • Aug 5MetaAnseems et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD014962 (Preprint) (meta analysis)meta-analysisRemdesivir for the treatment of COVID‐19Details   Review of 5 RCTs prior to April 17, 2021 showing mortality RR 0.93 [0.81-1.06] for hospitalized patients.
  • Aug 5MetaStricker et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.001 (Peer Reviewed) (meta analysis)death, ↓75.0%, p<0.0001Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-AnalysisDetails   Meta analysis of 11 HCQ PrEP studies in India covering 7,616 healthcare workers, showing significantly lower cases with treatment.
  • Aug 5In SilicoRana et al., Research Square, doi:10.21203/rs.3.rs-755838/v1 (Preprint)A Computational Study of Ivermectin and Doxycycline Combination Drug Against SARS-CoV-2 InfectionDetailsIn silico study showing strong binding affinity of ivermectin and doxycycline for SARS-CoV-2 main protease 3CLpro, and increased binding affinity for the combination of both.
  • Aug 4LateZhang et al., Therapeutic Advances in Gastroenterology, doi:10.1177/17562848211035670 (Peer Reviewed)hosp. time, ↓13.6%, p=0.009Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19Details   Retrospective 375 patients in China, 179 treated with probiotics (Bifidobacterium, Lactobacillus, and Enterococcus), showing improved clinical outcomes with treatment.
  • Aug 4LateÖzuygur Ermiş et al., Turkish Journal of Medical Sciences, doi:10.3906/sag-2009-64 (Peer Reviewed)The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on Hospital Mortality in COVID 19 Pneumonia PatientsDetails   Retrospective 370 hospitalized patients, 222 receiving HCQ+AZ and 148 receiving HCQ, showing mortality OR 0.61 [0.23-1.59], p = 0.31 for the addition of AZ.
  • Aug 4PrEPBhatt et al., medRxiv, doi:10.1101/2021.08.02.21260750 (Preprint)cases, ↑49.3%, p=0.02Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care WorkersDetails   Observational study of 927 low-risk healthcare workers in India, 731 volunteering for weekly HCQ prophylaxis, showing higher cases with treatment in unadjusted results. Clinical outcome was in the protocol, however no information on which..
  • Aug 4LateAlghamdi et al., Saudi Pharmaceutical Journal, doi:10.1016/j.jsps.2021.08.008 (Peer Reviewed)death, ↑39.2%, p=0.52Clinical characteristics and treatment outcomes of severe (ICU) COVID-19 patients in Saudi Arabia: A single centre studyDetails   Retrospective 171 ICU patients in Saudi Arabia showing no significant difference for HCQ treatment in unadjusted results.
  • Aug 3ReviewSantin et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100924 (Review) (Peer Reviewed)reviewIvermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19Details   Review concluding that the evidence supports worldwide use of ivermectin for COVID-19, complementary to immunization. Authors note that it is likely non-epitope specific, possibly retaining efficacy with new viral strains. They note that ..

Puntiamo a coprire i trattamenti precoci più promettenti per COVID-19. Usiamo criteri prestabiliti di estrazione degli effetti che danno priorità agli esiti più gravi, per i dettagli vedi i metodi. Per gli esiti specifici e le diverse fasi del trattamento vedi le singole pagine. Non tutti i trattamenti sono coperti qui, l’efficacia è stata riportata per molti altri trattamenti negli studi. Degli 878 studi, 600 presentano risultati che si confrontano con un gruppo di controllo, 532 sono studi di trattamento, e 68 analizzano i risultati basati sui livelli di siero. Ci sono 12 studi su animali, 25 studi in silico, 46 studi in vitro e 56 meta analisi.

Vi preghiamo di inviarci correzioni, aggiornamenti o commenti. I vaccini e i trattamenti sono entrambi estremamente preziosi e complementari. Tutti i mezzi pratici, efficaci e sicuri dovrebbero essere utilizzati. L’eliminazione del COVID-19 è una corsa contro l’evoluzione virale. Nessun trattamento, vaccino o intervento è disponibile al 100% ed efficace per tutte le varianti attuali e future. Negare l’efficacia di qualsiasi metodo aumenta il rischio che il COVID-19 diventi endemico e aumenta la mortalità, la morbilità e i danni collaterali. Non forniamo consigli medici. Prima di prendere qualsiasi farmaco, consulta un medico qualificato che può fornire consigli personalizzati e dettagli su rischi e benefici in base alla tua storia medica e alla tua situazione. I protocolli di trattamento per i medici sono disponibili presso il FLCCC.

https://c19early.com/ (in costante aggiornamento)

PS: quindi altrove non si studiano solo i vaccini, si studiano trattamenti e cure precoci perché (eh sono obbligati a scriverlo, fatevene una ragione di narrativa) il virus va trattato precocemente e vanno valutati i migliori risultati.
Avete fatto caso che molti elementi sono naturali e non solo farmaci?
Non potevano nemmeno scrivere che è una associazione di elementi che permette la performance migliore per ottenere ottimi risultati pre-ricovero.
Quindi i protocolli e le cure che qui in Italia ostacolano, altrove sono analizzate in modo oculato per raggiungere una migliore risultato per curare le persone, a qualsiasi livello.
E come mi fanno notare il corona virus esiste da moltissimo tempo e ci sono tantissimi prodotti già conosciuti che funzionano contro il virus.
Osservate le tabelle quanti rimedi naturali riportano.
Quindi il vaccino sempre promosso non è l’unica soluzione performante e a buon mercato.
Del resto altrove si distribuisce già questo, e riescono anche a contenere benissimo i costi, senza porre obblighi e continue vessazioni a nessuno

Noo tranquilli, da noi è solo pura follia parlarne, e se ne parli sei una volgare antivax, ma questa è la narrativa, e del resto ieri abbiamo visto la carica.
A ben pensarci hanno troppa fretta in questa mano di poker, mi sembra cha abbiano troppa fretta di andare in all in.

….. Ehm ora ragazzi vi lascio che vado a cucinare, e vado prima a vedere quanta merce ho in frigorifero, e quanta è quella prossima alla scadenza, ehm una casalinga non spreca mai nulla e massimizza l’economia domestica: nulla si butta e la prima a scadere si prepara e si serve.
Caro italiano vorrai mica buttare quello che hai in frigo e tutto quello che hai già ordinato?
Ehm sì una brava casalinga deve gestire anche gli ordini inviati ai fornitori, questi vanno sempre pagati, mica puoi buttare via, sai è un tale spreco che è un peccato.
Ora ragazzi vi lascio, devo rimestare ragù e annaffiare i gerani…

PSS: se cercate l’immagine qua trovate tutti i suoi capolavori e le sue bellissime fotografie https://stevephoto.com/ e bellissime immagini rare della Valle d’Aosta, e come lavora.